Lutathera
Showing 26 - 43 of 43
Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor Trial (procedure, drug, other)
Not yet recruiting
- Metastatic Midgut Neuroendocrine Tumor
- Unresectable Midgut Neuroendocrine Tumor
- Biospecimen Collection
- +5 more
- (no location specified)
Mar 16, 2023
Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)
Recruiting
- Extensive Stage Small Cell Lung Cancer
- [177Lu]Lu-DOTA-TATE
- +4 more
-
Lille, France
- +6 more
Jan 23, 2023
Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)
Not yet recruiting
- Metastatic Neuroendocrine Tumor
- Biospecimen Collection
- +4 more
- (no location specified)
Feb 10, 2023
Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,
Recruiting
- Advanced Lung Carcinoid Tumor
- +11 more
- Everolimus
- Lutetium Lu 177 Dotatate
-
Boston, Massachusetts
- +1 more
Jul 19, 2022
Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor Trial (Lutathera)
Not yet recruiting
- Carcinoid Heart Disease
- +2 more
- Lutathera
- (no location specified)
Aug 3, 2020
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage Trial in Washington, Hackensack (Nivolumab,
Completed
- Small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Nivolumab
- 177Lu-DOTA0-Tyr3-Octreotate
-
Washington, District of Columbia
- +1 more
Feb 22, 2021
Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)
Recruiting
- Neuroendocrine Neoplasm
- Biospecimen Collection
- +4 more
-
Duarte, California
- +3 more
Jan 12, 2023
Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour Trial in France (Positron emission
Recruiting
- Neuroendocrine Tumor
- +2 more
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
- +3 more
-
Bordeaux, France
- +3 more
Nov 18, 2021
Metastatic Digestive System Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in United States (Lutetium Lu 177
Recruiting
- Metastatic Digestive System Neuroendocrine Neoplasm
- Metastatic Neuroendocrine Tumor
- Lutetium Lu 177 Dotatate
- Triapine
-
Phoenix, Arizona
- +10 more
Aug 23, 2022
Spanish Series of Patients Treated With Radionuclide Lutetium177
Recruiting
- Neuroendocrine Tumors
- +17 more
- Lutetium [177Lu] oxodotreotide/dotatate
-
Santiago De Compostela, A Coruña, Spain
- +18 more
Jul 1, 2021
Metastatic Merkel Cell Carcinoma Trial in Australia (Avelumab, External Beam Radiation Therapy (EBRT), Lutetium-177
Recruiting
- Metastatic Merkel Cell Carcinoma
- Avelumab
- +2 more
-
Sydney, New South Wales, Australia
- +5 more
Apr 21, 2021
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour Trial in Worldwide (Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate)
Completed
- Carcinoid Tumor of the Small Bowel
- Neuroendocrine Tumour
- Octreotide LAR
- 177Lu-DOTA0-Tyr3-Octreotate
-
Los Angeles, California
- +38 more
Mar 10, 2022
Semi-automated Segmentation Methods of SSTR PET for Dosimetry
Not yet recruiting
- Refractory Meningioma
- To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
- (no location specified)
Sep 8, 2022
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,
Not yet recruiting
- Neuroendocrine Neoplasia's (NENs)
- Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
-
Basel, SwitzerlandDivision of Nuclear Medicine, University Hospital Basel
Apr 27, 2022
Carcinoma, Neuroendocrine Trial in Edmonton ([177]Lu-DOTA-TATE)
Recruiting
- Carcinoma, Neuroendocrine
-
Edmonton, Alberta, CanadaCross Cancer Institute
Apr 12, 2021
Neuroendocrine Tumors Trial in United States (177Lu-DOTA0-Tyr3-Octreotate)
Approved for marketing
- Neuroendocrine Tumors
-
Gilbert, Arizona
- +40 more
Apr 5, 2018